PYXS Logo

Pyxis Oncology, Inc. (PYXS) 

NASDAQ
Market Cap
$238.19M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
686 of 776
Rank in Industry
372 of 433

Largest Insider Buys in Sector

PYXS Stock Price History Chart

PYXS Stock Performance

About Pyxis Oncology, Inc.

Pyxis Oncology, Inc., a preclinical stage biopharmaceutical company, engages in the development of therapies to treat cancers. Its immune-oncology product candidates include PYX-106, an investigational fully human immunoglobulin G1 isotype siglec-15 targeting antibody for the treatment of thyroid cancer, head and neck squamous cell carcinoma, non-small cell lung cancer (NSCLC), and other solid tumors; and PYX-102, an investigational immune-therapeutic for treatment of solid tumors. The company's antibody drug conjugate (ADC) product candidates …

Insider Activity of Pyxis Oncology, Inc.

Over the last 12 months, insiders at Pyxis Oncology, Inc. have bought $0 and sold $0 worth of Pyxis Oncology, Inc. stock.

On average, over the past 5 years, insiders at Pyxis Oncology, Inc. have bought $5.86M and sold $2.7M worth of stock each year.

There was no buying activity among insiders over the last 12 months.

The last purchase of 8,000 shares for transaction amount of $14,960 was made by Connealy Pamela Ann (CFO and COO) on 2023‑09‑28.

List of Insider Buy and Sell Transactions, Pyxis Oncology, Inc.

2023-09-28PurchaseCFO and COO
8,000
0.0167%
$1.87$14,960+78.43%
2023-09-27PurchaseCFO and COO
6,426
0.0147%
$1.85$11,868+97.55%
2023-09-27PurchaseChief Accounting Officer
2,500
0.0058%
$1.87$4,675+97.55%
2023-09-25PurchaseCFO and COO
12,000
0.0257%
$1.67$20,044+103.93%
2023-09-25PurchaseChief Accounting Officer
5,000
0.0113%
$1.77$8,850+103.93%
2023-09-22PurchaseCFO and COO
5,000
0.0124%
$1.74$8,695+126.88%
2023-09-22PurchaseChief Accounting Officer
2,500
0.0062%
$1.74$4,349+126.88%
2023-09-18SalePresident and CEO
8,541
0.02%
$2.10$17,936+76.96%
2023-09-14SalePresident and CEO
100
0.0002%
$2.25$225+64.22%
2023-09-13SalePresident and CEO
3,000
0.007%
$2.27$6,816+59.38%
2023-09-12SalePresident and CEO
4,917
0.0114%
$2.25$11,071+60.36%
2023-09-11SalePresident and CEO
20,000
0.045%
$2.27$45,414+54.35%
2023-03-17Purchase10 percent owner
1.81M
5.1245%
$2.76$5M-10.51%
2022-04-21Sale
1.75M
6.1916%
$3.05$5.32M-16.98%
2021-12-08Purchasedirector
10,000
0.0316%
$9.39$93,885-71.08%
2021-11-18Purchasedirector
15,700
0.048%
$12.74$200,018-78.75%
2021-10-13Purchasedirector
312,500
1.3218%
$16.00$5M-70.72%
2021-10-13Purchase
450,000
1.9034%
$16.00$7.2M-70.72%

Insider Historical Profitability

<0.0001%
PFIZER INC10 percent owner
5952263
10.0168%
$4.0110<0.0001%
Cormorant Asset Management, LP
1118854
1.8829%
$4.0110<0.0001%
Connealy Pamela AnnCFO and COO
818532
1.3775%
$4.0140
Wadhane JitendraChief Accounting Officer
226937
0.3819%
$4.0130
Civik Thomasdirector
15700
0.0264%
$4.0110<0.0001%

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Deep Track Capital Lp$17.82M7.114.18MNew+$17.82M0.08
Laurion Capital Management LP$16.45M6.563.86M+21.77%+$2.94M0.12
Balyasny Asset Management Llc$11.05M4.412.59MNew+$11.05M0.03
Ikarian Capital LLC$7.08M2.821.66MNew+$7.08M0.97
The Vanguard Group$5.97M2.381.4M+7.25%+$403,592.37<0.0001
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.